10-Q: Zeo ScientifiX Boosts Revenue, Faces Going Concern Warning

Zeo ScientifiX reported a 32.7% revenue increase and reduced net loss, but continues to face substantial doubt about its ability to continue as a going concern amidst regulatory and legal challenges.

Summary

• Revenues for the three months ended January 31, 2026, increased by 32.7% to $1,446,000, up from $1,090,000 in the prior year period.
• Net loss for the quarter improved to $(852,000) from $(1,243,000) in the same period last year.
• Cash used in operating activities increased to $(471,000) for the quarter, compared to $65,000 cash provided in the prior year.
• The company raised $1,200,000 from November 2025 to January 2026 and an additional $650,000 in February 2026 through private offerings of common stock and warrants.
• A 'going concern' warning remains, with an accumulated deficit of $68,586,000 and a working capital deficit of $879,000 as of January 31, 2026.
• Zeo ScientifiX is pursuing clinical research and commercial sales strategies compliant with Florida's new stem cell therapy law (SB 1768), effective July 1, 2025.
• Disclosure controls and procedures were deemed not effective as of January 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While revenue growth and reduced net loss are positive, the persistent 'going concern' warning, increased cash burn from operations, and ineffective disclosure controls indicate significant underlying financial and operational instability. The capital raises are crucial for survival but highlight ongoing funding needs.

Positives

• Total revenues increased by 32.7% to $1,446,000 for the three months ended January 31, 2026, compared to $1,090,000 in the prior year.
• Net loss decreased by 31.5% to $(852,000) for the quarter, an improvement from $(1,243,000) in the same period last year.
• Loss from operations improved by $375,000, reaching $(878,000) for the quarter.
• The company's cash balance significantly increased to $1,030,000 at January 31, 2026, from $221,000 at October 31, 2025, primarily due to financing activities.
• Strategic focus on Florida's new stem cell therapy law (SB 1768) is expected to create substantial new demand and accelerate clinical trial objectives at reduced cost.
• Launched an IRB-approved clinical study for Patient Pure X (PPX) in musculoskeletal joint pathologies, with 7 patients enrolled and 5 clinics participating.
• General and administrative expenses decreased by 5.1% due to reduced stock-based compensation costs.

Negatives

• The company continues to incur significant net losses, with a net loss of $(852,000) for the quarter.
• Cash used in operating activities increased substantially to $(471,000) for the quarter, indicating increased cash burn.
• A working capital deficit of $(879,000) and an accumulated deficit of $(68,586,000) persist as of January 31, 2026.
• The company's independent auditors and management have concluded there is substantial doubt about its ability to continue as a going concern for the next 12 months.
• Disclosure controls and procedures were evaluated as not effective as of January 31, 2026, and material weaknesses in internal control over financial reporting were noted in the prior annual report.
• Gross profit margin slightly decreased to 80.6% from 82.5% in the prior year period.
• Multiple ongoing legal proceedings could result in significant costs and adverse outcomes.

Risks

• Inability to establish a stabilized source of sufficient revenues to cover operating costs.
• Potential restrictions on the company's ability to process, sell, and distribute its products due to FDA regulations (Section 351 of the Public Health Services Act) requiring approved biologics license applications (BLA).
• Dependence on additional investment capital to fund ongoing operating expenses and research and development costs, with future funding likely to be costly and dilutive.
• Lack of assets to pledge for borrowing additional capital.
• Reliance on the ability to produce and sell products subject to changing technology and regulations.
• Current market capitalization, common stock liquidity, and available authorized shares may hinder the ability to raise equity proceeds.
• No assurance that research and development activities will be successful or that required costs can be timely funded.
• Adverse outcomes from ongoing legal proceedings (Neurovive, Dr. Golub, Exotropin, BioXtek) could harm the business.
• Ineffective disclosure controls and material weaknesses in internal control over financial reporting pose risks to financial reporting reliability and compliance.

Future Outlook

The company anticipates significant revenue growth and faster advancement of its clinical trial objectives at reduced cost due to Florida's new stem cell therapy law (SB 1768), effective July 1, 2025. It expects to collect real-world safety and outcome data from providers, which should lower risks for future FDA submissions. Zeo ScientifiX plans to continue advancing its research programs, including clinical studies, product development, and ongoing quality and compliance initiatives, while also exploring further development of topical aesthetic products. However, the company remains dependent on additional investment capital to fund ongoing operating expenses and research and development costs, and future funding is expected to be costly and dilutive.

Management Comments

• Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur.
• Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products.
• We believe that our products are compliant and fall within the respective guidelines (SB 1768) and intend to vigorously defend against any adverse interpretation by the FDA and/or the state of Florida on the classification of our products that may be deemed as not being compliant under currently defined regulations, if any.

Industry Context

StockSavvy.ai notes that Zeo ScientifiX is strategically positioning itself to capitalize on Florida's new stem cell therapy law (SB 1768), which could significantly open up the market for non-FDA-approved stem cell and human tissue-derived therapies within the state. This legislative change provides a unique, state-level regulatory pathway that could differentiate Zeo from competitors operating solely under federal FDA guidelines, potentially accelerating product adoption and clinical data collection. The company's focus on ethically sourced birth tissue products and autologous biologics aligns with growing interest in regenerative medicine, but the broader industry still faces significant regulatory hurdles at the federal level, making state-specific legislation like SB 1768 a critical, albeit localized, market driver.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Neurovive Holding Co., LLC, Paragon Medical Group, LLC, and Dr. David Buechner filed a complaint on January 26, 2026, in Arkansas, asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment, and conversion related to a proposed clinical trial and funding. Plaintiffs seek injunctive relief and unspecified compensatory damages. The company disputes all allegations.
• Dr. Howard Golub filed a complaint on November 19, 2024, in Florida, alleging breach of contract for the company's failure to pay $150,000 severance following the non-renewal of his employment agreement. The company intends to vigorously defend against the lawsuit.
• Exotropin filed a complaint on August 29, 2025, in Florida, for declaratory judgment concerning the termination of a Sales Representative Agreement, and later amended it on January 7, 2026, to add claims for breach of contract and breach of fiduciary duty, seeking injunctive and monetary relief. The company terminated the agreement for cause on August 15, 2025, and filed counterclaims for unjust enrichment and tortious interference.
• The company commenced an action against BioXtek on December 17, 2025 (amended January 5, 2026), in Florida, asserting claims for breach of contract, implied covenant, fraudulent inducement, violation of the Florida Deceptive Unfair Trade Practices Act, equitable accounting, and declaratory judgment, seeking damages and equitable relief. This follows BioXtek's attempt to terminate a Binding MOU and Joint Venture in June 2025. BioXtek has not yet been served.

Related Party Transactions

• Sales of approximately $2,000 (2026) and $32,000 (2025) to a management services organization (MSO) in which Dr. George Shapiro, the company's Chief Medical Officer and a board member, has an indirect economic interest.
• The company invested $145,000 in Exotropin, a privately-held skin-care formulator, in which Greyt Ventures, LLC (a principal shareholder) and Skycrest Holdings, LLC (a former principal shareholder) each own a 17.93% interest. The company's CMO also has an option to acquire up to 200,000 membership interests in Exotropin.
• Grant of 175,000 shares of common stock to Greyt Ventures LLC, a principal shareholder, in consideration of consulting services rendered to the company on January 14, 2026.

Stakeholder Impact

• **Shareholders**: Experience dilution from recent and potential future capital raises, but also benefit from increased cash reserves. The 'going concern' warning and legal proceedings introduce significant risk to investment value. Improved revenue and reduced net loss offer a glimmer of operational progress.
• **Employees**: Dr. Kisiday's appointment as CTO and stock grants to key executives (CEO, CMO) indicate investment in leadership and retention. However, the 'going concern' status could create job insecurity.
• **Customers (Doctors and Clinics)**: The company's focus on compliance with Florida's SB 1768 aims to provide a clearer pathway for using its products, potentially increasing product availability and adoption. Ongoing regulatory uncertainty with the FDA could still impact product access.
• **Creditors**: The 'going concern' warning and working capital deficit indicate elevated risk. The company's ability to meet obligations depends on successful revenue stabilization and further financing.
• **Regulatory Authorities (FDA, Florida)**: The company's operations are under scrutiny regarding compliance with FDA regulations for biologics and the new Florida stem cell law. Any adverse rulings could severely impact the business model.

Next Steps

• Complete already approved clinical studies and obtain approval for additional studies for specific indications.
• Continue efforts to expand sales internationally and develop new product offerings and/or designations to mitigate FDA regulatory risks.
• Continue to pursue clinical research and commercial sales strategies compliant with Florida's SB 1768.
• Enroll up to 350 patients in the IRB-approved clinical study for PPX in musculoskeletal joint pathologies.
• Address material weaknesses in internal control over financial reporting and improve disclosure controls and procedures.

Key Dates

Recommendation

While Zeo ScientifiX demonstrated positive revenue growth and a reduced net loss, the persistent 'going concern' warning, significant cash burn from operations, and a working capital deficit present substantial financial risks. The recent capital raises provide temporary liquidity but highlight an ongoing reliance on external funding, which is expected to be dilutive. The strategic focus on Florida's SB 1768 offers a potential growth catalyst, but regulatory uncertainties with the FDA and multiple ongoing legal proceedings add considerable risk. Given the mixed signals of operational improvement alongside severe financial and governance challenges, a 'hold' recommendation is appropriate for investors who are already exposed and willing to monitor developments closely, but new investment carries high speculative risk.

Keywords

regenerative medicine, biopharmaceutical, stem cell therapy, FDA regulations, SB 1768, Zofin, Patient Pure X, biologics, quarterly report, going concern, private placement, stock-based compensation